First in a series. This morning, my oldest son, Julian, 30, called me from Philadelphia, where he is living for two months before packing up his bags and moving again. He is a professional entertainer hoping to sing on Broadway one day. Currently, he’s on his first national tour for…
Discussion
This season, we’ve seen terrible natural disasters. Tropical storms, wildfires, mudslides, earthquakes, and flash floods have destroyed communities worldwide. Watching news reports from these places is heartbreaking. We may not know how to respond to seeing people covered in mud searching for loved ones or coming home to find only…
Discussion
Alvotech and Lotus Pharmaceutical are teaming up on plans to commercialize AVT87, a proposed biosimilar to Hemlibra (emicizumab). Lisa Graver, CEO of Alvotech, said in a company press release that the companies “look forward to working together” to broaden access to high-quality biologics. Hemlibra is an…
Discussion
Lately, I have been trying to spend as little as I reasonably can. I decided to enter a season of aggressively paying down debt. Even writing that makes me slightly uneasy. I have a personal concern about announcing goals: Sometimes saying what I plan to do gives me enough…
Discussion
Acquired hemophilia can leave patients and their families feeling fearful and out of control. Clear information, ongoing medical follow-up, and good support systems are important for helping them regain confidence and a sense of normalcy, according to a study from Sweden based on interviews with patients and their family…
Becoming educated and informed about hemophilia is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your hemophilia journey.
There is no cure for hemophilia yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
